Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14886179 | 0.74 | PLA2G10 (0.36) | BRD4CYP19A1PDPK1 | |
| SCHEMBL9910776 | 0.72 | BCAT2 (0.43) | ADORA3ADORA2AADORA2BADORA1PDPK1 | |
| SCHEMBL14883234 | 0.69 | GABRA1 (0.33) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL18197671 | 0.67 | ALDH1A1 (0.44) | — | |
| SCHEMBL28119075 | 0.67 | PTGS2 (0.44) | — | |
| SCHEMBL28119077 | 0.66 | ALDH1A1 (0.44) | METADORA1 | |
| SCHEMBL12444953 | 0.65 | PIP4K2C (0.47) | — | |
| SCHEMBL6698002 | 0.65 | ADRB2 (0.41) | CYP19A1PDPK1 | |
| SCHEMBL17679286 | 0.63 | HCRTR2 (0.39) | — | |
| SCHEMBL16011605 | 0.63 | BCAT2 (0.59) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | BRD4 1687/4885MET 2514/4885ADORA3 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.